Latest Conference Articles

MOMENTUM Aims to Complete Development of Momelotinib for Myelofibrosis Treatment

MOMENTUM Aims to Complete Development of Momelotinib for Myelofibrosis Treatment

June 16th 2022, 4:24pm

ASCO Annual Meeting

Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.

Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma

Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma

June 8th 2022, 2:00pm

ASCO Annual Meeting

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

Positive Responses Shown With Rivoceranib in Patients With Adenoid Cystic Carcinoma

Positive Responses Shown With Rivoceranib in Patients With Adenoid Cystic Carcinoma

June 8th 2022, 1:00pm

ASCO Annual Meeting

Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.

Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer

Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer

June 8th 2022, 12:27am

ASCO Annual Meeting

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors

Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors

June 7th 2022, 6:20pm

ASCO Annual Meeting

At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.

Selinexor Improves PFS in Patients with Endometrial Cancer and in Those with p53 Wild-type Status

Selinexor Improves PFS in Patients with Endometrial Cancer and in Those with p53 Wild-type Status

June 7th 2022, 5:54pm

ASCO Annual Meeting

Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

Reduced Risk of Metastatic Progression With Darolutamide in Patients With nmCRPC

Reduced Risk of Metastatic Progression With Darolutamide in Patients With nmCRPC

June 7th 2022, 3:24pm

ASCO Annual Meeting

Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

Intensified Chemotherapy Does Not Improve Efficacy With Panitumumab in mCRC

Intensified Chemotherapy Does Not Improve Efficacy With Panitumumab in mCRC

June 7th 2022, 2:05pm

ASCO Annual Meeting

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers

LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers

June 7th 2022, 1:16pm

ASCO Annual Meeting

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases

FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases

June 7th 2022, 1:07pm

ASCO Annual Meeting

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.